Intervacc is now, after many years of research, in the final development stage of Strangvac®, a modern equine strangles vaccine. The Company’s Marketing Authorization Application (MAA) for review of Strangvac® has recently been submitted to the European Medicines Agency (EMA).
Equine strangles is highly contagious infectious disease, caused by the bacterium Streptococcus equi, that affects horses globally. Today veterinarians, horse owners and affected horses around the world testify that a safe and effective vaccine against equine strangles is not yet on the market.
Strangvac®, consisting only of soluble recombinant proteins, is injected intramuscularly and totally devoid of any living infectious agent. This results in a well-tolerated vaccine with only mild, local and transient side effects, as expected of a modern vaccine.
Innovative technology offers new opportunities
The vaccine has been developed with an innovative technology and is based on fusions of recombinant proteins. The research behind the vaccine’s technical platform has been done together with researchers at Karolinska Institute and the Swedish University of Agricultural Sciences, SLU.
The MAA for Strangvac® is based on a successful series of clinical trials demonstrating the safety, immune response, efficacy and DIVA capability. DIVA (Differentiation of Infected from Vaccinated Animals) capability is a key feature during epidemics in order to distinguish vaccinated animals from asymptomatic carriers.